Compugen (CGEN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Compugen (CGEN) has a cash flow conversion efficiency ratio of 0.056x as of December 2022. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA4.33 Million ≈ $11.60K USD) by net assets (ILA77.68 Million ≈ $208.26K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CGEN equity financing ratio to measure how much of total assets are equity-financed.
Compugen - Cash Flow Conversion Efficiency Trend (1999–2024)
This chart illustrates how Compugen's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Compugen (CGEN) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Compugen Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Compugen ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nam Kim Steel JSC
VN:NKG
|
0.104x |
|
Humax Co. Ltd
KQ:115160
|
-0.018x |
|
Compania Espanola de Viviendas en Alquiler SA
MC:CEV
|
0.006x |
|
Tatung System Technologies
TWO:8099
|
-0.024x |
|
HomesToLife Ltd
NASDAQ:HTLM
|
0.084x |
|
The ONE Enterprise Public Company Limited
BK:ONEE-R
|
N/A |
|
SC II Acquisition Corp. Class A ordinary share
NASDAQ:SCII
|
14.005x |
|
Yuan High-Tech Development Co Ltd
TWO:5474
|
-0.011x |
Annual Cash Flow Conversion Efficiency for Compugen (1999–2024)
The table below shows the annual cash flow conversion efficiency of Compugen from 1999 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Compugen.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ILA54.91 Million ≈ $147.22K |
ILA49.60 Million ≈ $132.99K |
0.903x | +265.02% |
| 2023-12-31 | ILA65.56 Million ≈ $175.76K |
ILA-35.89 Million ≈ $-96.21K |
-0.547x | -24.65% |
| 2022-12-31 | ILA77.68 Million ≈ $208.26K |
ILA-34.11 Million ≈ $-91.46K |
-0.439x | -105.95% |
| 2021-12-31 | ILA106.69 Million ≈ $286.04K |
ILA-22.75 Million ≈ $-60.99K |
-0.213x | +9.81% |
| 2020-12-31 | ILA119.78 Million ≈ $321.13K |
ILA-28.32 Million ≈ $-75.92K |
-0.236x | +67.51% |
| 2019-12-31 | ILA38.32 Million ≈ $102.74K |
ILA-27.89 Million ≈ $-74.77K |
-0.728x | -103.92% |
| 2018-12-31 | ILA37.24 Million ≈ $99.85K |
ILA-13.29 Million ≈ $-35.63K |
-0.357x | +65.90% |
| 2017-12-31 | ILA29.30 Million ≈ $78.54K |
ILA-30.66 Million ≈ $-82.19K |
-1.046x | -235.38% |
| 2016-12-31 | ILA63.52 Million ≈ $170.29K |
ILA-19.82 Million ≈ $-53.13K |
-0.312x | -9.54% |
| 2015-12-31 | ILA89.90 Million ≈ $241.01K |
ILA-25.61 Million ≈ $-68.65K |
-0.285x | -170.78% |
| 2014-12-31 | ILA105.97 Million ≈ $284.12K |
ILA-11.15 Million ≈ $-29.89K |
-0.105x | +47.90% |
| 2013-12-31 | ILA31.89 Million ≈ $85.49K |
ILA-6.44 Million ≈ $-17.26K |
-0.202x | +67.10% |
| 2012-12-31 | ILA17.67 Million ≈ $47.38K |
ILA-10.85 Million ≈ $-29.08K |
-0.614x | -29.93% |
| 2011-12-31 | ILA19.58 Million ≈ $52.50K |
ILA-9.25 Million ≈ $-24.80K |
-0.472x | -212.23% |
| 2010-12-31 | ILA28.29 Million ≈ $75.83K |
ILA-4.28 Million ≈ $-11.47K |
-0.151x | +44.39% |
| 2009-12-31 | ILA27.40 Million ≈ $73.45K |
ILA-7.45 Million ≈ $-19.98K |
-0.272x | +72.82% |
| 2008-12-31 | ILA10.00 Million ≈ $26.82K |
ILA-10.01 Million ≈ $-26.84K |
-1.001x | -105.79% |
| 2007-12-31 | ILA17.29 Million ≈ $46.34K |
ILA-8.41 Million ≈ $-22.54K |
-0.486x | -26.03% |
| 2006-12-31 | ILA25.74 Million ≈ $69.00K |
ILA-9.93 Million ≈ $-26.63K |
-0.386x | -25.94% |
| 2005-12-31 | ILA36.25 Million ≈ $97.18K |
ILA-11.11 Million ≈ $-29.78K |
-0.306x | -24.48% |
| 2004-12-31 | ILA49.57 Million ≈ $132.88K |
ILA-12.20 Million ≈ $-32.71K |
-0.246x | -164.19% |
| 2003-12-31 | ILA59.81 Million ≈ $160.34K |
ILA-5.57 Million ≈ $-14.94K |
-0.093x | +29.28% |
| 2002-12-31 | ILA68.88 Million ≈ $184.67K |
ILA-9.08 Million ≈ $-24.33K |
-0.132x | -11.08% |
| 2001-12-31 | ILA80.06 Million ≈ $214.64K |
ILA-9.50 Million ≈ $-25.46K |
-0.119x | -78.69% |
| 2000-12-31 | ILA92.51 Million ≈ $248.02K |
ILA-6.14 Million ≈ $-16.46K |
-0.066x | +85.27% |
| 1999-12-31 | ILA12.79 Million ≈ $34.28K |
ILA-5.76 Million ≈ $-15.45K |
-0.451x | -- |
About Compugen
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical tria… Read more